TY - JOUR T1 - Research news in clinical context JF - Sexually Transmitted Infections JO - Sex Transm Infect SP - 237 LP - 238 DO - 10.1136/sextrans-2021-055335 VL - 98 IS - 3 AU - Stefano Rusconi AU - Kristine E Shields AU - Ana Arias AU - Sonia Raffe AU - Marina Daskalopoulou Y1 - 2022/05/01 UR - http://sti.bmj.com/content/98/3/237.abstract N2 - Treatment with Paxlovid (nirmatrelvir/ritonavir 300/100 mg two times per day for 5 days) is expected to play an important role in patients with mild-to-moderate COVID-19 who are at risk of disease progression. Nirmatrelvir targets the SARS-CoV-2 3CL protease, whereas ritonavir acts as a pharmacological enhancer. Paxlovid is an inhibitor of CYP3A (Cytochrome P450, family 3, subfamily A) and may increase plasma concentrations of drugs that are primarily metabolised by CYP3A. Guidance has been released to indicate that people with HIV or hepatitis C virus who take Paxlovid can continue their antiviral treatment, including regimens containing ritonavir or cobicistat, without interruption or dose adjustments. With concomitant use, patients should be monitored for a potentially increased risk of adverse events. Other important interactions exist, including reduced Paxlovid therapeutic effect by drugs that induce CYP3A, that require careful management.1 Infectious Diseases Society of America and HIV Medicine Association. Paxlovid for the treatment of COVID-19: considerations for people with HIV and hepatitis C. December 31, 2021. https://www.idsociety.org/globalassets/covid-19-real-time-learning-network/patient-populations/hiv/oral-covid-tx-considerations-for-people-with-hiv-and-hcv.pdf.Studies on the association between depression and condomless sex have reported discordant findings. One possible explanation is that participants who report no recent sexual intercourse are merged with those who report condom-protected sex into a single ‘no condomless sex’ comparator group. Using data from two cross-sectional cohorts … ER -